ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Phathom Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 171.75% and Operating profit at -183.29% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -11.11
2
With a growth in Net Sales of 94.12%, the company declared Very Positive results in Sep 25
- RAW MATERIAL COST(Y) Fallen by -2.26% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -106.02 %
- NET SALES(Q) Highest at USD 49.5 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 58.15%, its profits have risen by 19.1%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 58.15% in the last 1 year, much higher than market (S&P 500) returns of 11.87%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Phathom Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Phathom Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Phathom Pharmaceuticals, Inc.
58.15%
-0.01
126.03%
S&P 500
11.87%
0.62
19.30%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
171.75%
EBIT Growth (5y)
-183.29%
EBIT to Interest (avg)
-11.11
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0.28
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.95
EV to EBIT
-5.94
EV to EBITDA
-5.96
EV to Capital Employed
54.39
EV to Sales
8.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-915.34%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -2.26% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -106.02 %
NET SALES(Q)
Highest at USD 49.5 MM
OPERATING PROFIT(Q)
Highest at USD -15.12 MM
OPERATING PROFIT MARGIN(Q)
Highest at -30.53 %
PRE-TAX PROFIT(Q)
Highest at USD -29.97 MM
NET PROFIT(Q)
Highest at USD -29.97 MM
EPS(Q)
Highest at USD -0.41
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 284.73 MM
Here's what is working for Phathom Pharmaceuticals, Inc.
Net Sales
At USD 49.5 MM has Grown at 202.74%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 49.5 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -15.12 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -30.53 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -29.97 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -29.97 MM has Grown at 64.98%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -29.97 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -29.97 MM has Grown at 64.98%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.41
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -106.02 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -2.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Phathom Pharmaceuticals, Inc.
Cash and Eqv
Lowest at USD 284.73 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
